Warning: The NCBI web site requires JavaScript to function. more...
Division of Systems Toxicology, National Center for Toxicological Research, FDA, Jefferson, AR 72079, USA. lei.guo@fda.hhs.gov
The association of kava products with liver-related health risks has prompted regulatory action in many countries. We used a genome-wide gene expression approach to generate global gene expression profiles from the livers of male B6C3F1 mice administered kava extract by gavage for 14 weeks, and identified the differentially expressed drug metabolizing genes in response to kava treatments. Analyses of gene functions and pathways reveal that the levels of significant numbers of genes involving drug metabolism were changed and that the pathways involving xenobiotics metabolism, Nrf2-mediated oxidative stress response, mitochondrial functions and others, were altered. Our results indicate that kava extract can significantly modulate drug metabolizing enzymes, potentially leading to herb-drug interactions and hepatotoxicity.
Published by Elsevier Ltd.
Images from this publication.See all images (7) Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on